Sarepta Therapeutics (SRPT) EBT (2016 - 2025)
Historic EBT for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $153.6 million.
- Sarepta Therapeutics' EBT rose 103160.49% to $153.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $373.0 million, marking a year-over-year increase of 49940.86%. This contributed to the annual value of $260.8 million for FY2024, which is 15013.94% up from last year.
- According to the latest figures from Q2 2025, Sarepta Therapeutics' EBT is $153.6 million, which was up 103160.49% from $171.7 million recorded in Q4 2024.
- In the past 5 years, Sarepta Therapeutics' EBT registered a high of $171.7 million during Q4 2024, and its lowest value of -$512.7 million during Q1 2023.
- Its 5-year average for EBT is -$71.4 million, with a median of -$47.9 million in 2021.
- Per our database at Business Quant, Sarepta Therapeutics' EBT tumbled by 86330.21% in 2021 and then skyrocketed by 103160.49% in 2025.
- Quarter analysis of 5 years shows Sarepta Therapeutics' EBT stood at -$121.9 million in 2021, then rose by 16.89% to -$101.3 million in 2022, then soared by 139.85% to $40.4 million in 2023, then surged by 325.41% to $171.7 million in 2024, then dropped by 10.54% to $153.6 million in 2025.
- Its EBT stands at $153.6 million for Q2 2025, versus $171.7 million for Q4 2024 and $34.0 million for Q3 2024.